News – Page 873 – Endpoints News

Revolution Med shoots for $100M+ IPO — and divulges some secrets about that Warp Drive buyout

6 years ago

At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell

6 years ago

Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO

6 years ago

Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel

6 years ago

China’s fourth richest man takes a back seat at the top drugmaker he built

6 years ago

Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication

6 years ago

In active shopping mode, Eli Lilly plots one deal per quarter as it scouts 'Dermira-like' assets up to $5B

6 years ago

First Chinese biotech on Nasdaq in two years draws $104M

6 years ago

Germany’s IQWiG finds first tumor-agnostic drug provides no added benefit

6 years ago

Hung jury vote leaves FDA with a difficult decision on Durect's non-opioid painkiller

6 years ago

BioMarin execs discuss some eye-popping numbers for the price of valrox — but haven't we heard this before?

6 years ago

#JPM20: Five years after first PCSK9, Novartis goes for win as Sanofi moves on, Amgen salvages what's left

6 years ago

Mayo Clinic launches clinical analytics platform with nference; WuXi buys German plant from Bayer

6 years ago

The FDA: Faster, but not necessarily better. And that could threaten the agency's brand

6 years ago

#JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of ...

6 years ago

Frazier closes 12th fund in 30 years, with $617M to bet on cell/gene therapy, Big Pharma spinoffs and more

6 years ago

Neon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal

6 years ago

Biopharma's China plan gets a boost from patent protections sealed in now official trade deal

6 years ago

Government spending bill tweak means 3 more NDAs will become BLAs, FDA says

6 years ago

GSK, Pfizer contradict on the future of consumer health JV — report

6 years ago

#JPM20: After a year of NASH collapses, all eyes on two biotechs

6 years ago

Video Replay: Endpoints at #JPM20 — newsmakers on dealmaking, pricing and manufacturing

6 years ago

Publisher's note

Celgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available

6 years ago

FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing

6 years ago

First page Previous page 870 871 872873874 875 876 Next page Last page